stjude.org
Genomic profiling identifies specific genetic alterations associated with cancer susceptibility, relapse risk and how tumors respond to therapeutics. These studies allow scientists and clinicians to predict how patients are likely to respond to therapy, providing insights that shape the treatment of childhood ALL. Results from this collaborative study demonstrate the importance of genomic profiling in accurately determining patient risk in B-ALL, in conjunction with traditional criteria.
“We are planning to reduce conventional therapies in the future for children with ALL because we know that many patients can be cured with less therapy,” explained co-senior author, Mignon Loh, MD, leader of Seattle Children’s Cancer and Blood Disorders Center, COG ALL Committee chair emeritus, Seattle Children’s Ben Towne Center for Childhood Cancer Research director, and head of Seattle Children’s Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy. “We want to make sure we accurately identify those children, and because of the special design of the study, this project allowed us to do just that.”
The scientists conducted genome and transcriptome sequencing on both SR B-ALL samples that relapsed and samples that remained in complete remission in a one:two ratio. They found that ALL subtypes, genetic alterations and patterns of aneuploidy (extra or missing chromosomes) were associated with the risk of relapse and time to relapse. Some B-ALL subtypes, such as hyperdiploid and ETV6::RUNX1 ALL, had a low frequency of relapse, but others including PAX5-altered, TCF3/4::HLF, ETV6::RUNX1-like and BCR::ABL1-like were associated with an increased risk of relapse. Notably, the specific type of genetic changes within those B-ALL subtypes further influenced the risk of relapse. This work demonstrated that genetic variations and cancer subtypes influence relapse risk in SR B-ALL, and patients classified as standard-risk can have tumors with high-risk features.
“Whole genome sequencing was important to accurately and comprehensively identify these changes, and they could not all have been identified without it,” explained Mullighan. “Children with SR ALL should have their tumor cell genome sequenced upon their initial diagnosis to identify if their tumor cells have these high-risk features, so that their initial therapy intensity can be increased.”
“Beyond conventional therapies, this information could also be used to develop and explore novel, personalized treatment strategies,” added Loh.
The study’s co-first authors are Ti-Cheng Chang and Wenan Chen of St. Jude.
The study’s other authors are Mary Shago, University of Toronto; Karen Rabin, Baylor College of Medicine; Elizabeth Raetz, William Carroll, Perlmutter Cancer Center; Anne Angiolillo, Children’s National Medical Center; Michael Borowitz, John Hopkins University; Michael Burke, Medical College of Wisconsin; Andrew Carroll, University of Alabama at Birmingham; I-Ming Chen, Richard Harvey; University of New Mexico, Albuquerque; Nyla Heerema, The Ohio State University; Jeremy Wang, University of North Carolina at Chapel Hill; Eric Larsen, Maine Children’s Cancer Program; Leonard Mattano, HARP Pharma Consulting; Kelly Maloney, University of Colorado; Nilsa Ramirez, Nationwide Children’s Hospital and The Ohio State University; Wanda Salzer, Uniformed Services University; Cheryl Willman, Mayo Clinic; Naomi Winick, University of Texas Southwestern Medical Center; Brent Wood, University of Southern California; Stephen Hunger, Children’s Hospital of Philadelphia and the University of Pennsylvania; and Chunxu Qu, Zhongshan Chen, Dale Hedges, Abdelrahman Elsayed, Stanley Pounds, Meenakshi Devidas, Cheng Cheng, Pradyuamma Baviskar, Ilaria Iacobucci, Sima Jeha, Ching-Hon Pui, and Gang Wu, St. Jude.
The study was supported by the National Institutes of Health (R35 CA197695 and CA21765), the Cancer Moonshot (HHSN261201500003I) and ALSAC, the fundraising awareness organization of St. Jude.